An In-Depth Analysis of the Investigational Compound GS-1720 and Clarification of the "GS-17" Designation

Executive Summary

This report provides a comprehensive analysis of the medication designated "GS-17," a query that encompasses multiple distinct pharmaceutical, supplemental, and investigational entities. Initial analysis reveals that the designation is ambiguous. The pill imprint "G 17" refers to at least two different commercially available medications: an over-the-counter analgesic and sleep aid combining diphenhydramine and naproxen sodium, and a prescription urinary tract analgesic, phenazopyridine hydrochloride. Furthermore, "GS 17 CAP" is the name of a multivitamin supplement produced in India. However, the most significant and data-rich subject associated with this nomenclature is the investigational compound GS-1720, a novel, long-acting oral antiretroviral for the treatment of HIV-1 infection developed by Gilead Sciences.

GS-1720 is an integrase strand transfer inhibitor (INSTI) designed for once-weekly administration, representing a potential paradigm shift from the current standard of daily oral therapy. Developed to be co-administered with GS-4182 (a prodrug of the capsid inhibitor lenacapavir), the combination regimen aims to address the unmet need for more convenient HIV treatment options, potentially improving long-term adherence and quality of life for people with HIV. Early-phase clinical trials demonstrated a promising profile for GS-1720, characterized by potent antiviral activity, a high barrier to resistance, a long pharmacokinetic half-life suitable for weekly dosing, and a favorable initial safety profile in both healthy volunteers and people with HIV.

Based on this encouraging data, Gilead Sciences advanced the combination into two large-scale, pivotal Phase 2/3 clinical trials known as the WONDERS program, comparing the weekly regimen directly against its own market-leading daily pill, Biktarvy. However, the development program was abruptly halted in June 2025 when the U.S. Food and Drug Administration (FDA) placed a full clinical hold on all five trials involving GS-1720 and GS-4182. The hold was initiated due to the identification of a critical safety signal: decreases in CD4+ T-cell and absolute lymphocyte counts in a subset of trial participants. This adverse event is particularly concerning for an HIV therapy, as the primary goal of treatment is immune reconstitution.

This development is not without precedent, echoing a similar clinical hold placed on Merck’s investigational long-acting oral agent, islatravir, for the same safety signal in 2021. The recurrence of this specific form of lymphopenia in two different long-acting oral programs from different drug classes suggests a potential fundamental pharmacological challenge associated with maintaining high intracellular drug concentrations for extended periods. The future of the GS-1720 program is now uncertain, pending a thorough investigation by Gilead. This event has significant strategic implications for the company and may influence the future trajectory of HIV drug development, potentially shifting focus toward non-oral long-acting delivery systems.

I. Introduction: Deconstructing the "GS-17" Designation

The user query for a report on "GS-17" requires an initial clarification, as this designation and the similar imprint code "G 17" do not refer to a single, unique entity. Instead, they are associated with a range of disparate products across the pharmaceutical and supplemental landscape, as well as with non-medical terminologies. Establishing a clear understanding of these different entities is a critical first step before proceeding to a detailed analysis of the most clinically and strategically significant subject among them.

Pill Imprint "G 17": Over-the-Counter and Prescription Medications

A common source of the "G 17" identifier is its use as an imprint code on solid oral dosage forms, which helps in the identification of a drug's composition, strength, and manufacturer. Research reveals that this specific imprint is used on several distinct medications.

Analgesic and Hypnotic Combination

A blue, capsule-oblong pill, 15 mm in size, bearing the imprint "G 17" has been identified as a combination product containing 25 mg of Diphenhydramine Hydrochloride and 220 mg of Naproxen Sodium.[1] This medication is available over-the-counter (OTC) and is indicated for the treatment of insomnia associated with pain.[1] Diphenhydramine is a first-generation antihistamine with sedative properties, while naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that provides pain relief. The combination is marketed under brand names such as Aleve PM. The manufacturer associated with this specific imprinted pill is Granules India Ltd..[1] It is classified as an analgesic combination and is not a controlled substance.[1]

Urinary Tract Analgesic

The imprint "G 17" also appears on a brown, round, 10 mm pill. This product has been identified as Phenazopyridine Hydrochloride at a strength of 200 mg.[2] Phenazopyridine is a urinary tract analgesic used to relieve symptoms of pain, burning, and urgency associated with urinary tract infections and other urinary tract irritations, such as dysuria and interstitial cystitis.[3] It is available both over-the-counter at lower strengths and by prescription at the 200 mg strength.[3] The supplier for this particular product is Westminster Pharmaceuticals, LLC.[3] This drug belongs to the class of miscellaneous genitourinary tract agents and is not a controlled substance.[3]

Contraceptive Placebo Tablet

Further complicating the identification, the "G 17" imprint is also used for the inert placebo tablets included in several oral contraceptive packs. These brown, round pills contain 75 mg of ferrous fumarate, an iron supplement intended to be taken during the hormone-free interval to reduce the risk of anemia.[2] Contraceptive brands using this placebo tablet include Hailey Fe 1/20, Hailey Fe 1.5/30, and Hailey 24 Fe.[2]

Nutritional Supplement: "GS 17 CAP"

Separate from the pill imprints, a product named "GS 17 CAP" is marketed as a nutritional supplement. This product is manufactured by Madhav Biotech in India and is a multivitamin and multi-mineral formulation.[4] Its extensive list of ingredients includes Ascorbic acid (25 mg), Ginseng (42.5 mg), Ferrous sulphate (30 mg), Cholecalciferol (200 IU), and numerous other vitamins and minerals.[4] It is promoted for helping growth and good health, and for treating or preventing vitamin C deficiency.[4] This product is distinct from regulated pharmaceuticals and falls into the category of dietary supplements.[4]

Investigational Antiretroviral Drug: "GS-1720"

The most complex and scientifically significant entity related to the query is the investigational compound GS-1720. This is a novel, potent, oral antiretroviral drug being developed by the biopharmaceutical company Gilead Sciences.[5] GS-1720 belongs to the class of integrase strand transfer inhibitors (INSTIs) and is being studied for the treatment of HIV-1 infection.[5] Its key differentiating feature is its design as a long-acting agent intended for once-weekly oral dosing.[5] As an investigational drug, GS-1720 is not yet approved for marketing in any jurisdiction and is currently undergoing clinical trials to establish its safety and efficacy.[5]

Biological Target: "RGS17"

The designation "RGS17" refers not to a drug, but to a protein: Regulator of G protein signaling 17. RGS17 is a member of a protein family that modulates cellular signaling pathways initiated by G-protein-coupled receptors (GPCRs).[9] Increased expression of RGS17 has been implicated in the progression of certain cancers, including prostate and lung cancer, making it a subject of research as a potential therapeutic

target for new cancer drugs.[9] It is a component of human biology, not a medicinal product administered to patients.

Non-Medical Designations

To ensure a fully exhaustive response, it is noted that "GS-17" has appeared in non-medical contexts. Historically, it was one of the three "supergrade" levels (GS-16, GS-17, and GS-18) in the U.S. Federal Government's General Schedule pay scale, which were eliminated by the Civil Service Reform Act of 1978 and replaced by the Senior Executive Service.[11] Additionally, the term "G.S. 78C-17" appears in the North Carolina General Statutes, referring to legal requirements for investment advisers.[13] These contexts are unrelated to pharmacology or medicine.

Rationale for Focus

Given the depth and complexity of the available research material, which includes extensive preclinical data, detailed clinical trial designs, and significant regulatory developments, this report will focus exclusively on the investigational drug GS-1720. While the other entities are correctly identified by similar names or codes, GS-1720 represents a frontier of pharmaceutical innovation with substantial clinical and commercial implications, making it the most relevant subject for an in-depth, expert-level analysis. The following table provides a summary to resolve the initial ambiguity of the query.

Table 1: Disambiguation of the "GS-17" Designation
Designation	Entity Name / Composition	Type / Use	Developer / Supplier	Regulatory Status
G 17 (imprint)	Diphenhydramine HCl (25 mg) / Naproxen Sodium (220 mg)	OTC Analgesic / Hypnotic	Granules India Ltd.	Over-the-counter (OTC) 1
G 17 (imprint)	Phenazopyridine HCl (200 mg)	Urinary Tract Analgesic	Westminster Pharmaceuticals, LLC	Rx and/or OTC 3
G 17 (imprint)	Ferrous Fumarate (75 mg)	Placebo Tablet in Oral Contraceptives	(Various)	Rx 2
GS 17 CAP	Multivitamin / Multi-mineral / Ginseng	Nutritional Supplement	Madhav Biotech (India)	Supplement 4
GS-1720	GS-1720 (Bavtavirine)	Investigational HIV-1 INSTI	Gilead Sciences, Inc.	Investigational (Phase 2/3) 5
RGS17	Regulator of G protein signaling 17	Biological Protein / Therapeutic Target	N/A (Endogenous Protein)	N/A 9
GS-17 (historical)	General Schedule Pay Grade 17	U.S. Civil Service Pay Scale	U.S. Government	Defunct (since 1978) 11

II. GS-1720: Profile of an Investigational Long-Acting Antiretroviral

GS-1720 is a novel compound at the forefront of efforts to evolve the management of HIV-1 infection. Its development is rooted in a clear strategic vision to address the remaining challenges in a therapeutic area that has already seen remarkable progress. This section details the profile of GS-1720, including its developer, mechanism of action, and the specific unmet need it is designed to fill.

Developing Company and Strategic Focus

GS-1720 is under development by Gilead Sciences, a global biopharmaceutical company widely recognized as a leader in the field of virology, and particularly for its portfolio of transformative HIV treatments and prevention therapies.[5] The company's research and development pipeline is robust, with 52 clinical-stage programs spanning its core therapeutic areas of virology, oncology, and inflammation.[14] Gilead has publicly stated an ambition to deliver more than ten transformative therapies by the year 2030, a goal that underscores its commitment to pioneering science and innovation.[14] The development of GS-1720 fits squarely within this strategy, representing an attempt to create a next-generation therapy that could redefine the standard of care in HIV treatment.

The strategic context for developing a new HIV drug is particularly noteworthy for Gilead. The company's revenue is heavily reliant on its flagship HIV franchise, led by the once-daily, single-tablet regimen Biktarvy, a multi-billion dollar product that dominates the market.[16] The development of a once-weekly oral regimen like GS-1720, which is being tested directly against Biktarvy in pivotal trials, is a proactive and aggressive strategy. It represents an attempt to innovate beyond its own successful products, effectively creating a successor that could extend its market leadership long after the patents on its current blockbusters expire. This approach, while carrying the risk of cannibalizing existing sales, is a classic strategy to preempt generic competition and address the "innovator's dilemma" by disrupting one's own market before a competitor does. The high stakes of this strategy highlight the immense importance of the GS-1720 program to Gilead's long-term vision.

Drug Class and Mechanism of Action

GS-1720 is classified as an Integrase Strand Transfer Inhibitor (INSTI).[5] This is a well-established and highly effective class of antiretroviral drugs. The mechanism of action of INSTIs involves the specific inhibition of the HIV-1 integrase enzyme. This enzyme plays a crucial role in the viral replication cycle by catalyzing the insertion, or "integration," of viral DNA into the host cell's genome. By blocking this step, INSTIs effectively prevent the virus from establishing a chronic infection within the host's immune cells (primarily CD4+ T-cells) and subsequently halt its ability to replicate.[19] Other highly successful INSTIs that form the backbone of modern HIV therapy include bictegravir and dolutegravir.[20] GS-1720 leverages this proven mechanism but is distinguished by its unique molecular structure, which confers a pharmacokinetic profile designed for

long-acting oral administration.[5]

Therapeutic Goal and Unmet Need

The primary therapeutic goal for GS-1720 is the treatment of HIV-1 infection.[5] While the advent of once-daily, single-tablet regimens has revolutionized HIV care, making treatment simpler and more tolerable than ever before, a significant unmet need persists. The requirement for daily medication, taken for a lifetime, can impose a considerable burden on people with HIV (PWH).[19] This can lead to "treatment fatigue," contribute to challenges with adherence, and serve as a constant reminder of their HIV status, which can carry social stigma.[22]

Sub-optimal adherence is a critical issue in HIV management, as it can lead to incomplete viral suppression, the development of drug-resistant viral strains, and ultimately, treatment failure.[22] A medication that can be taken orally just once a week has the potential to be transformative. By significantly reducing the dosing frequency, such a regimen could substantially ease the treatment burden, improve adherence and persistence, and enhance the overall quality of life for PWH.[6] GS-1720 is therefore positioned not merely as another effective drug, but as a potential paradigm shift in the lived experience of HIV treatment, moving from daily management to a weekly routine.[24]

Combination Therapy Strategy

It is a fundamental principle of HIV medicine that treatment must consist of a combination of at least two active antiretroviral drugs from different classes to effectively suppress the virus and prevent the emergence of resistance. Consequently, GS-1720 is not being developed as a standalone agent but as part of a complete, two-drug, once-weekly regimen.[5]

Its partner agent in clinical trials is GS-4182.[5] GS-4182 is a prodrug of

lenacapavir, another innovative, long-acting antiretroviral developed by Gilead.[5] A prodrug is an inactive compound that is metabolized in the body to produce the active drug, often to improve absorption or other pharmacokinetic properties. Lenacapavir belongs to a new and distinct drug class known as

capsid inhibitors. It disrupts the HIV-1 capsid, a protein shell essential for multiple stages of the viral lifecycle, including nuclear entry and the assembly of new virus particles.

The strategy is to combine two novel, potent, long-acting agents with different mechanisms of action—an INSTI (GS-1720) and a capsid inhibitor (lenacapavir, via GS-4182)—to create a synergistic and robust regimen that can be administered orally on a once-weekly basis.[5] This approach leverages Gilead's deep pipeline in HIV and represents a highly innovative attempt to construct the first-ever complete, long-acting oral regimen.

III. Preclinical and Early Phase Clinical Development of GS-1720

Before advancing to large-scale pivotal trials, any investigational drug must undergo rigorous preclinical and early-phase clinical evaluation to establish its fundamental properties. For GS-1720, this process generated a compelling body of data that supported its potential as a once-weekly oral agent, demonstrating high potency, a favorable resistance profile, and what appeared to be a clean bill of health in terms of initial safety and tolerability.

Preclinical Profile: Potency and Resistance

In vitro studies are crucial for determining a drug's intrinsic antiviral activity and its vulnerability to resistance mutations. In this regard, GS-1720 performed exceptionally well.

• Potency: Laboratory assays demonstrated that GS-1720 possesses improved antiviral potency when compared directly to bictegravir, the INSTI component of Biktarvy and a recognized best-in-class agent.[19] It exhibited a potent half-maximal inhibitory concentration (IC50) against the HIV integrase enzyme of 6.2 nM.[31] This high level of potency is a prerequisite for a long-acting drug, as it allows for effective viral suppression to be maintained even as drug concentrations naturally decline between doses.
• Resistance Profile: A critical attribute for any new antiretroviral is its resilience against drug resistance. GS-1720 showed a high barrier to the development of resistance in vitro and maintained activity against a wide array of HIV-1 strains that already harbor resistance mutations to other INSTIs.[19] Its in vitro resistance profile was found to be comparable to that of bictegravir and notably superior to older INSTIs such as cabotegravir, raltegravir, and elvitegravir.[19] Studies indicated that the development of high-level resistance to GS-1720 would require the accumulation of at least three distinct mutations in the integrase gene, a significantly higher genetic barrier than for many earlier drugs.[19] Furthermore, in viral breakthrough assays designed to simulate sub-optimal drug levels, clinically relevant concentrations of GS-1720 successfully prevented viral replication.[7]

Phase 1a Clinical Trial (Healthy Volunteers)

The first-in-human studies for GS-1720 were conducted in healthy adult volunteers without HIV to assess its safety, tolerability, and pharmacokinetics (PK). The results from these Phase 1a studies were highly encouraging and provided the foundational data for its proposed dosing schedule.

• Pharmacokinetics (PK): The PK profile of GS-1720 was the standout finding. The drug demonstrated a long terminal half-life of approximately 9.3 days.[6] This is substantially longer than daily oral drugs and strongly supports the feasibility of a once-weekly dosing interval. The studies also revealed nonlinear pharmacokinetics, where drug exposure (measured by Cmax and AUC) increased less than proportionally as the dose was escalated.[6] This suggests a saturation mechanism in the drug's absorption or clearance pathways. The median time to reach maximum plasma concentration (Tmax) was a consistent 4 hours across doses.[6]
• Safety and Tolerability: In these initial human studies, GS-1720 was found to be generally well-tolerated. Across both single and multiple ascending dose cohorts, there were no reports of serious adverse events (AEs), no Grade 3 or 4 AEs, and no clinically significant laboratory abnormalities.[6] In the multiple ascending dose (MAD) portion of the study, which involved dosing for up to 6 weeks, AEs were reported in 12 of 45 participants (27%), but the vast majority (80%) were mild (Grade 1). Only one participant, in the 450 mg weekly dose cohort, discontinued the study due to an adverse event.[18] This clean initial safety profile was a critical milestone, providing the confidence to proceed with studies in people with HIV.

Phase 1b Clinical Trial (People with HIV)

Following the successful Phase 1a trials, a Phase 1b study was conducted in people with HIV (who were either treatment-naïve or had been off therapy for at least 12 weeks) to gain the first proof-of-concept of the drug's antiviral efficacy in vivo.

• Antiviral Efficacy: GS-1720 demonstrated potent and rapid antiviral activity. In participants who received a loading dose of 450 mg on days 1 and 2, the drug achieved a mean reduction in plasma HIV-1 RNA of more than 2.0 log10 copies/mL (a 99% reduction) by day 11.[8] This level of viral load decline is robust and comparable to that seen with the most effective daily oral INSTIs, confirming that the drug's in vitro potency translates to a strong clinical effect.
• Pharmacodynamics: The study established a clear relationship between drug concentration and antiviral response. Robust viral load reductions were consistently observed in participants whose GS-1720 concentrations on day 11 remained above a key pharmacodynamic threshold known as the two-fold inhibitory quotient (IQ2).[8]
• Resistance: A pivotal finding from this study was the absence of treatment-emergent INSTI resistance. Even in participants who had lower-than-expected drug concentrations, no new resistance mutations were detected by day 11.[8] This provided early validation of the drug's high barrier to resistance in a clinical setting.
• Safety: In this population, GS-1720 continued to be generally well-tolerated. Some participants reported transient and mild adverse events, including nausea, headache, or vomiting, which are not uncommon with the initiation of antiretroviral therapy.[21]

The successful completion of these early-phase trials painted a picture of a highly promising drug candidate. The data provided a strong scientific rationale for advancing GS-1720 into larger, more definitive trials. However, a significant disconnect exists between this overwhelmingly positive early safety data and the specific, serious safety signal that would later emerge and halt the entire program. The absence of any signal of lymphopenia or significant laboratory abnormalities in these comprehensive Phase 1 studies suggests that the toxicity is not an acute, easily detectable effect. Instead, it points toward a more complex phenomenon that may only manifest with longer-term drug exposure, or perhaps as an emergent property of the combination with GS-4182, a synergy that was not evaluated in these initial single-agent studies. This gap between early and late-stage safety findings highlights the inherent risks of drug development and the limitations of short-term studies in predicting all potential long-term outcomes.

Table 2: Summary of Phase 1 Clinical Trial Results for GS-1720
Study Phase	Population	Dose(s) Tested	Key Pharmacokinetic Findings	Key Efficacy Finding	Summary of Safety/Tolerability
Phase 1a	Healthy Adults without HIV 6	Single Ascending Doses (50-1350 mg); Multiple Ascending Doses (150-1350 mg) 6	Half-life: ~9.3 days; Tmax: 4 hours; Nonlinear PK 6	N/A	Generally well-tolerated; No serious AEs; No Grade 3/4 AEs; No clinically significant lab abnormalities 6
Phase 1b	People with HIV (INSTI-naïve) 19	30, 150, 450, 900 mg 8	Concentrations correlated with antiviral response 8	Viral Load Reduction: >2.0 log10 copies/mL by Day 11 (450 mg dose) 19	Generally well-tolerated; No treatment-emergent INSTI resistance observed 8

IV. The WONDERS Program: Pivotal Phase 2/3 Clinical Trials

Building on the strong foundation of preclinical and Phase 1 data, Gilead Sciences launched an ambitious clinical development program named WONDERS to definitively evaluate the efficacy and safety of its once-weekly oral regimen. This program, comprising two large-scale, pivotal Phase 2/3 trials, was designed to provide the necessary evidence for regulatory approval by testing the combination of GS-1720 and GS-4182 in two of the most important populations in HIV treatment.

Program Overview

The WONDERS program consists of two parallel, randomized, active-controlled, operationally seamless Phase 2/3 studies: WONDERS-1 and WONDERS-2.[19] The "seamless" design is a modern clinical trial approach that allows a study to progress from a mid-stage (Phase 2) evaluation directly into a late-stage (Phase 3) confirmatory phase without interruption, accelerating the development timeline. The choice of an active comparator was a bold strategic move: in both trials, the investigational weekly regimen was tested against Gilead's own Biktarvy, the most widely prescribed HIV treatment globally and the undisputed standard of care.[5] This design set a very high bar for success, requiring the new regimen to prove it was at least as effective as the market leader, with the primary advantage being its more convenient dosing schedule.

WONDERS-1 (NCT06544733): The "Switch" Study

The WONDERS-1 trial was designed to evaluate the regimen in people with HIV who were already virologically suppressed on their current therapy.[26] This "switch" population represents a large and important market segment for new HIV drugs.

• Population: The trial enrolled adults with HIV-1 who had achieved and maintained an undetectable viral load (HIV-1 RNA < 50 copies/mL) for at least 24 weeks while taking daily Biktarvy.[26] The estimated enrollment for the study was 675 participants.[35]
• Design: Participants were randomized to either switch from daily Biktarvy to the once-weekly oral combination of GS-1720 and GS-4182, or to continue taking daily Biktarvy.[26]
• Primary Endpoint: The primary objective was to demonstrate that the weekly regimen was non-inferior to daily Biktarvy in maintaining viral suppression. This was measured by the proportion of participants who experienced virologic failure (defined as having an HIV-1 RNA level of 50 copies/mL or higher) at Week 24 for the Phase 2 portion and at Week 48 for the Phase 3 portion of the study.[26]

WONDERS-2 (NCT06613685): The "Treatment-Naïve" Study

The WONDERS-2 trial was designed to assess the regimen's efficacy in initiating treatment for individuals who had never before received antiretroviral therapy.[5] This "treatment-naïve" setting is the other major indication for any new first-line HIV therapy.

• Population: This study enrolled treatment-naïve adults with HIV-1 who had a screening viral load of at least 500 copies/mL.[5] The estimated enrollment was also 675 participants.[7]
• Design: Participants were randomized to receive either the investigational once-weekly regimen of GS-1720 plus GS-4182 or the standard-of-care daily Biktarvy.[5]
• Primary Endpoint: The primary goal was to demonstrate non-inferiority to Biktarvy in achieving virologic suppression. The endpoint was defined as the proportion of participants with an HIV-1 RNA level below 50 copies/mL at Week 24 (Phase 2) and Week 48 (Phase 3).[5]

Dosing Regimen in Trials

The dosing for the investigational arm in both WONDERS trials was structured to quickly achieve and then maintain therapeutic drug concentrations. Participants assigned to the experimental regimen received a one-day oral loading dose of 1300 mg of GS-1720 and 600 mg of GS-4182 on the first day of the study.[5] Following this initial dose, they transitioned to a weekly maintenance regimen of 650 mg of GS-1720 and 300 mg of GS-4182.[5] The study protocols also included plans to eventually transition participants to a fixed-dose combination (FDC) tablet containing both drugs, which would further simplify the regimen.[5]

Key Exclusion Criteria

The eligibility criteria for the WONDERS trials were designed to ensure patient safety and the integrity of the study data. Both trials shared several key exclusion criteria, including pre-existing genotypic resistance to INSTIs, any prior use of long-acting antiretrovirals like injectable cabotegravir or lenacapavir, and the presence of significant kidney or liver disease.[5]

A particularly notable exclusion criterion was a CD4+ T-cell count below 200 cells/mm³ at the time of screening.[35] This is a standard practice in many HIV clinical trials to avoid enrolling individuals with advanced immunodeficiency, for whom treatment failure could have more severe consequences. In retrospect, this standard criterion becomes profoundly significant. The very safety signal that led to the program's suspension was a drug-induced decline in CD4 counts. This creates a striking paradox: the adverse effect observed in some participants could have induced a state of immunodeficiency that would have rendered them ineligible to even enter the trial. This elevates the safety concern from a simple adverse event to a fundamental challenge to the drug's therapeutic rationale. The primary purpose of an HIV therapy is to enable immune recovery, marked by a stable or rising CD4 count; a drug that causes a significant decline in this critical biomarker, even in a subset of patients, faces a formidable, and possibly insurmountable, development obstacle.

Table 3: WONDERS Clinical Trial Program Overview
Trial Identifier	Study Title	Phase	Population	Est. Participants	Intervention Arms	Primary Endpoint	Current Status
NCT06544733	WONDERS-1	2/3	Virologically Suppressed ("Switch") 26	675 35	1. Weekly GS-1720 + GS-41822. Daily Biktarvy 26	Virologic failure (HIV RNA ≥50) at Wk 48 26	Active, Not Recruiting (On FDA Clinical Hold) 26
NCT06613685	WONDERS-2	2/3	Treatment-Naïve 5	675 7	1. Weekly GS-1720 + GS-41822. Daily Biktarvy 5	Virologic success (HIV RNA <50) at Wk 48 5	Active, Not Recruiting (On FDA Clinical Hold) 38

V. The FDA Clinical Hold: Analysis of the CD4+ T-Cell Safety Signal

The trajectory of the GS-1720 development program took a dramatic and unexpected turn in mid-2025. After years of promising preclinical and early clinical results, the entire program was brought to an abrupt halt by a significant regulatory action from the U.S. Food and Drug Administration (FDA). This event represents the single most critical development in the history of GS-1720 and has profound implications for its future.

The Event: FDA Clinical Hold (June 2025)

On June 10, 2025, Gilead Sciences issued a public statement announcing that the FDA had placed a full clinical hold on all ongoing trials investigating the combination of GS-1720 and/or GS-4182.[40] This is one of the most serious regulatory actions that can be taken during clinical development, effectively pausing all study activities, including the enrollment of new participants and the dosing of current participants with the investigational drugs.[42] The hold was comprehensive, affecting a total of five studies: the two large Phase 2/3 WONDERS trials, as well as three smaller Phase 1 studies.[27]

The Safety Signal: Lymphopenia

The FDA's decision was not based on a lack of efficacy but on the identification of a specific and concerning safety signal. In a subset of participants who were receiving the combination of GS-1720 and GS-4182, investigators observed clinically significant decreases in both CD4+ T-cell counts and absolute lymphocyte counts.[27] This condition, known as lymphopenia, is a reduction in the number of lymphocytes (a type of white blood cell) in the bloodstream. Since CD4+ T-cells are a critical component of the immune system and are the primary cells targeted by HIV, a drug-induced reduction in their numbers is a highly paradoxical and undesirable effect for an HIV medication.[47] A low CD4 count is a hallmark of immunodeficiency and increases a person's risk of opportunistic infections; therefore, a therapy that causes this condition could potentially weaken the immune system, directly opposing the fundamental goal of antiretroviral treatment.[17]

Gilead's Response and Current Status

In its official communication, Gilead acknowledged the clinical hold and the underlying safety signal. The company stated its intention to thoroughly investigate the cause of the lymphopenia and affirmed its commitment to working closely with the FDA to resolve the issues.[27] However, since the initial announcement, the company has not publicly released detailed data regarding the safety signal. Key information—such as the precise magnitude of the CD4 and lymphocyte declines, the number of participants affected, the proportion of the study population this represents, and whether the effect was more prominent in one of the WONDERS trials over the other—remains undisclosed.[44] As of the company's second-quarter 2025 financial results announcement in August 2025, the clinical hold remains in effect, with no specified timeline for resolution.[50]

Critical Precedent: The Islatravir Clinical Hold

The clinical hold on the GS-1720 program is particularly alarming because it is not an isolated event in the development of long-acting oral HIV therapies. In late 2021, Merck's highly anticipated investigational long-acting oral agent, islatravir, was also subjected to a full FDA clinical hold for the exact same safety signal: dose-related decreases in CD4+ T-cell and total lymphocyte counts.[43]

Islatravir belongs to a different drug class—nucleoside reverse transcriptase translocation inhibitors (NRTTIs)—but shares the same therapeutic goal of less frequent oral dosing. The investigation into the islatravir-associated lymphopenia pointed toward a mechanism involving the intracellular accumulation of the drug's active form (islatravir-triphosphate).[46] It was hypothesized that the very properties that made the drug long-acting—its ability to persist inside cells for extended periods—led to off-target effects on lymphocyte homeostasis.[46] Merck was eventually able to resume its islatravir treatment trials, but only at a substantially lower dose, a change that forced the company to abandon plans for monthly oral dosing for HIV prevention.[46]

The striking parallel between these two events, involving different companies and different drug classes, is difficult to ignore. The emergence of the same rare and counterintuitive toxicity in two of the most advanced long-acting oral antiretroviral programs suggests this may not be an idiosyncratic problem specific to one molecule. Instead, it raises the possibility of a fundamental pharmacological challenge inherent to the goal of long-acting oral therapy. The high and sustained intracellular drug concentrations required to achieve weekly or monthly dosing may, for some compounds, cross a threshold that leads to off-target cellular toxicity in lymphocytes. This hypothesis, if proven correct, would represent a major scientific and developmental hurdle for the entire field, suggesting that the quest for less frequent oral dosing has an unforeseen biological cost that must be understood and overcome.

Table 4: Comparative Analysis of Clinical Holds for Long-Acting Oral Antiretrovirals
Program	Drug Class(es)	Date of Hold	Stated Safety Signal	Hypothesized Mechanism	Program Outcome / Status
Gilead (GS-1720/GS-4182)	INSTI / Capsid Inhibitor	June 2025 42	Decreases in CD4+ T-cell and absolute lymphocyte counts 42	Under investigation; potential for intracellular accumulation or interaction toxicity	On full FDA clinical hold; future uncertain 42
Merck (Islatravir)	NRTTI	Dec 2021 43	Dose-dependent decreases in CD4+ T-cell and total lymphocyte counts 52	Intracellular accumulation of active metabolite leading to cellular toxicity 46	Resumed at lower dose for treatment; development for PrEP at higher doses halted 46

VI. Future Outlook and Strategic Implications for Gilead Sciences

The FDA clinical hold on the GS-1720 and GS-4182 program represents a significant inflection point, casting a shadow of uncertainty over a key pillar of Gilead's future HIV strategy. The path forward for the investigational regimen is now fraught with challenges, and the repercussions of this setback extend to the competitive landscape and investor sentiment.

Path to Resolving the Clinical Hold

Gilead's foremost priority is to conduct an exhaustive investigation into the root cause of the observed lymphopenia.[42] This process will involve a meticulous analysis of all available clinical and laboratory data from the five halted trials. Key questions that must be answered include:

• Is the effect dose-dependent?
• Is the toxicity attributable to GS-1720, GS-4182, or is it an emergent property of the combination?
• Is the effect limited to a specific patient subpopulation with identifiable risk factors?
• What is the underlying biological mechanism driving the lymphocyte decline?

The precedent set by Merck's islatravir program offers a potential, albeit challenging, roadmap. One possible path forward could involve restarting the trials with a lower dose of GS-1720 and/or GS-4182.[46] However, this approach is not without significant risk. A dose reduction might mitigate the toxicity, but it could also compromise the drug's pharmacokinetic profile, potentially making a once-weekly dosing schedule unviable. If the regimen must be dosed more frequently, it would lose its primary competitive advantage over highly effective daily pills like Biktarvy, thereby undermining its entire value proposition. The fact that the hold was extended to early-phase Phase 1 studies suggests that the FDA may require more fundamental, nonclinical toxicology and pharmacology work before permitting a return to large-scale human trials.[27]

Impact on the Competitive Landscape

The delay and uncertainty surrounding the WONDERS program have significant implications for the competitive dynamics in the HIV market. This setback creates an opening for competitors who are also developing long-acting therapies. While Merck faced its own challenges with islatravir, it has continued to advance the compound at a lower dose in combination with other agents, potentially allowing it to gain ground.[55]

For Gilead, this event elevates the strategic importance of its other long-acting HIV programs. The company's pipeline is not solely reliant on GS-1720. Its injectable capsid inhibitor, lenacapavir, is a cornerstone of its long-acting strategy. Lenacapavir is already approved for multi-drug resistant HIV and is on the cusp of a major launch as a twice-yearly injection for HIV prevention (PrEP), an indication for which it has demonstrated exceptional efficacy.[16] The clinical hold on the oral prodrug GS-4182 does not appear to impact the regulatory trajectory or ongoing development of the injectable formulation of lenacapavir.[41] Gilead is also investigating injectable lenacapavir in combination with other agents, and these programs will now likely receive even greater focus and resources.

Finally, the challenges faced by the GS-1720 program serve to reinforce the formidable clinical profile of Biktarvy. As noted by some market analysts, the difficulty in developing a therapy that can improve upon Biktarvy's combination of high efficacy, a high barrier to resistance, and excellent safety and tolerability is immense.[41] This setback underscores that the bar for new entrants is exceptionally high, even for an incumbent leader like Gilead.

Financial and Investor Implications

The announcement of the FDA clinical hold had an immediate and predictable negative effect on Gilead's stock price, reflecting investor concern over the future of a key pipeline asset.[16] This event introduces a significant element of uncertainty into the company's long-term growth narrative, which was partly predicated on the successful development and launch of a next-generation, long-acting oral platform.

Despite this setback, Gilead's financial position remains strong. The company's existing HIV franchise, anchored by the continued commercial success of Biktarvy, generates substantial revenue and provides a financial cushion to absorb such R&D challenges.[16] However, the hold on GS-1720 complicates the long-term outlook. Analyst sentiment is currently mixed; while many brokerage firms maintain a positive "Outperform" recommendation on the stock, citing the strength of the existing portfolio and other pipeline assets, some valuation models, such as the GuruFocus GF Value, suggest a potential downside from current price levels, reflecting the increased risk profile.[61]

The clinical hold on GS-1720 and GS-4182 may inadvertently catalyze a broader strategic shift in the field of HIV therapy innovation. The development of long-acting antiretrovirals has been proceeding along two main paths: less frequent oral regimens (e.g., weekly) and long-acting injectables or implants (e.g., monthly, semi-annually, or annually).[24] The weekly oral option has been viewed as a highly desirable goal, offering a significant improvement in convenience over daily pills without the logistical and healthcare infrastructure challenges associated with injectable therapies.[22]

However, with two of the most advanced and promising oral programs—Merck's islatravir and Gilead's GS-1720 combination—now having encountered the same serious safety roadblock of lymphopenia, the feasibility of this approach is being called into question. This recurring toxicity suggests that the pharmacological requirements for a long-acting oral agent may carry inherent biological risks that are difficult to predict or mitigate. In parallel, injectable therapies like lenacapavir are demonstrating outstanding efficacy with dosing intervals of six months, and other novel modalities like broadly neutralizing antibodies and implants are advancing through pipelines.[57] This major setback in the oral space could therefore prompt a strategic recalculation across the industry. Pharmaceutical companies may choose to de-prioritize the high-risk, high-reward pursuit of long-acting oral drugs and instead channel greater investment toward perfecting and scaling injectable and implantable technologies. While these modalities have their own implementation hurdles, they do not appear to share this specific and problematic toxicity profile. Such a shift could fundamentally alter the trajectory of HIV research and development for the next decade.

VII. Conclusion

This report sought to provide a comprehensive analysis of the medication designated "GS-17." The investigation first revealed that this query is ambiguous, referring to several distinct entities. While the pill imprint "G 17" identifies common over-the-counter and prescription medications and "GS 17 CAP" denotes a nutritional supplement, the most significant subject is the investigational antiretroviral drug GS-1720.

Developed by Gilead Sciences, GS-1720 emerged from early-phase clinical trials as a highly promising compound. As a potent, long-acting oral integrase strand transfer inhibitor with a high barrier to resistance, it formed the cornerstone of a potential paradigm-shifting once-weekly HIV treatment regimen when combined with the lenacapavir prodrug, GS-4182. This regimen represented a direct attempt to innovate beyond the current daily-pill standard of care, addressing the persistent challenges of treatment fatigue and long-term adherence for people with HIV.

The program's promising trajectory was, however, abruptly and decisively halted in June 2025 by a full FDA clinical hold across all five of its clinical trials. This action was precipitated by a critical safety signal: the observation of decreased CD4+ T-cell and absolute lymphocyte counts in a subset of participants. This adverse event is profoundly counterintuitive for an HIV therapy, as it suggests a potential for immune suppression rather than reconstitution.

This development does not exist in isolation. It strikingly mirrors a similar setback faced by Merck’s investigational long-acting oral agent, islatravir, for the very same safety signal. This pattern suggests that the challenge may be systemic to the class of long-acting oral antiretrovirals, possibly linked to the high intracellular drug concentrations required to maintain efficacy between infrequent doses. The future of the GS-1720 program is now deeply uncertain and is entirely contingent on Gilead's ability to fully characterize and mitigate this toxicity to the satisfaction of regulatory authorities. The event serves as a stark reminder of the immense difficulty of improving upon the current highly effective and safe standards of HIV care and may ultimately reshape long-term R&D strategies in the field, potentially accelerating the pivot toward non-oral long-acting formulations such as injectables and implants.

Works cited

1. G 17 Pill Blue Capsule/Oblong 15mm - Pill Identifier - Drugs.com, accessed September 9, 2025, https://www.drugs.com/imprints/g-17-31412.html
2. G 17 Pill Images - Pill Identifier - Drugs.com, accessed September 9, 2025, https://www.drugs.com/imprints.php?imprint=g+17
3. G 17 Pill Brown Round 10mm - Pill Identifier - Drugs.com, accessed September 9, 2025, https://www.drugs.com/imprints/g-17-35204.html
4. GS 17 CAP ( MADHAV BIOTECH ) - MedPlusMart, accessed September 9, 2025, https://www.medplusmart.com/product/gs-17-cap_gs_10001
5. GS-1720 | LAPaL, accessed September 9, 2025, https://lapal.ch/compounds/gs-1720/export
6. Gilead's Phase 1a trial results indicate GS-1720 as a potential long-acting HIV treatment, accessed September 9, 2025, https://www.eatg.org/hiv-news/gileads-phase-1a-trial-results-indicate-gs-1720-as-a-potential-long-acting-hiv-treatment/
7. GS-1720 / Gilead - LARVOL DELTA, accessed September 9, 2025, https://delta.larvol.com/Products/?ProductId=f012989c-96e9-4f2a-9690-3f5d9f569dd5
8. GS-1720 - LAPaL, accessed September 9, 2025, https://lapal.medicinespatentpool.org/compounds/gs-1720
9. RGS17: an emerging therapeutic target for lung and prostate cancers - PMC, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3865709/
10. Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8046767/
11. General Schedule (US civil service pay scale) - Wikipedia, accessed September 9, 2025, https://en.wikipedia.org/wiki/General_Schedule_(US_civil_service_pay_scale)
12. POSITIONS IN SUPERGRADE LEVELS COMMITTEE ON POST OFFICE AND CIVIL SERVICE - GovInfo, accessed September 9, 2025, https://www.govinfo.gov/content/pkg/CPRT-92HPRT74778O/pdf/CPRT-92HPRT74778O.pdf
13. G.S. 78C-16 Page 1 Article 3. Registration and Notice Filing Procedures of Investment Advisers and Investment Adviser Represent, accessed September 9, 2025, https://www.ncleg.gov/EnactedLegislation/Statutes/PDF/BySection/Chapter_78C/GS_78C-16.pdf
14. Virology, Inflammation, & Oncology Pipeline - Gilead Sciences, accessed September 9, 2025, https://www.gilead.com/science/pipeline
15. Gilead Sciences, accessed September 9, 2025, https://www.gilead.com/
16. FDA Places Clinical Hold on Gilead's HIV Studies, Stock Down | Nasdaq, accessed September 9, 2025, https://www.nasdaq.com/articles/fda-places-clinical-hold-gileads-hiv-studies-stock-down
17. Gilead hit with FDA clinical hold for batch of HIV trials, accessed September 9, 2025, https://www.clinicaltrialsarena.com/news/gilead-hit-with-fda-clinical-hold-for-batch-of-hiv-trials/
18. 154. Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1 - Oxford Academic, accessed September 9, 2025, https://academic.oup.com/ofid/article/12/Supplement_1/ofae631.040/7988049
19. In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral INSTI in Clinical Development - CROI Conference, accessed September 9, 2025, https://www.croiconference.org/wp-content/uploads/sites/2/posters/2025/724-2025.pdf
20. FDA-Approved HIV Medicines | NIH - HIVinfo, accessed September 9, 2025, https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines
21. GS-1720 – a new integrase inhibitor taken once weekly - CATIE.ca, accessed September 9, 2025, https://www.catie.ca/treatmentupdate-253/gs-1720-a-new-integrase-inhibitor-taken-once-weekly
22. High Acceptability but Persistent Barriers to Implementation of Long-acting Injectable Antiretrovirals: A Nationwide Cross-sectional Survey of Ryan White Clinics in the United States - Oxford Academic, accessed September 9, 2025, https://academic.oup.com/ofid/article/12/4/ofaf192/8099473
23. LA/ER Injectable Therapy - LEAP, accessed September 9, 2025, https://longactinghiv.org/topics/laer-injectable-therapy?page=2
24. RajGandhi.ART What's Next.7.16.25.final 2 - NATAP, accessed September 9, 2025, https://www.natap.org/2025/IAS/RajGandhi.ART%20What's%20Next.7.16.25.final%202.pdf
25. The long-acting HIV treatment era is just beginning, accessed September 9, 2025, https://hivglasgow.org/the-long-acting-hiv-treatment-era-is-just-beginning/
26. Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in ..., accessed September 9, 2025, https://ctv.veeva.com/study/study-of-oral-weekly-gs-1720-and-gs-4182-versus-biktarvy-in-people-with-hiv-1-who-are-virologically
27. FDA slaps holds on five of Gilead's HIV studies - FirstWord Pharma, accessed September 9, 2025, https://firstwordpharma.com/story/5971130
28. A Phase 2/3 Study of Oral Weekly GS-1720 and GS-4182 in HIV-1 - TrialScreen, accessed September 9, 2025, https://app.trialscreen.org/trials/phase-2-3-oral-weekly-gs-1720-4182-compared-biktarvy-people-hiv-1-been-trial-nct06613685
29. Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | Clinical Research Trial Listing - CenterWatch, accessed September 9, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06613685/study-of-oral-weekly-gs-1720-and-gs-4182-compared-with-biktarvy-in-people-with-hiv-1-who-have-not-been-treated?state=NJ&city=Newark,
30. Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline, accessed September 9, 2025, https://www.gilead.com/news/news-details/2024/gilead-presents-research-data-across-its-broad-and-innovative-hiv-treatment-portfolio-and-pipeline
31. Update on HIV Medicine Emerging Challenges, December 3, 2024 - IAS-USA, accessed September 9, 2025, https://www.iasusa.org/wp-content/uploads/hiv/2024/dc/handouts/hiv24-dc-gulick-handouts.pdf
32. Gilead's Phase 1a Trial Results Indicate GS-1720 as a Potential Long-Acting HIV Treatment, accessed September 9, 2025, https://www.contagionlive.com/view/gilead-s-phase-1a-trial-results-indicate-gs-1720-as-a-potential-long-acting-hiv-treatment
33. 154. Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11778217/
34. Gileads Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health, accessed September 9, 2025, https://www.gilead.com/news/news-details/2024/gileads-innovative-hiv-treatment-research-pipeline-aims-to-address-unmet-needs-and-advance-public-health
35. Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed - UCSF Clinical Trials, accessed September 9, 2025, https://clinicaltrials.ucsf.edu/trial/NCT06544733
36. Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1) - Gilead Clinical Trials, accessed September 9, 2025, https://www.gileadclinicaltrials.com/study?nctid=NCT06544733
37. An Operationally Seamless Phase 2/3 Randomized Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of GS-1720 in Combination With GS-4182 Versus Biktarvy in Virologically Suppressed People With HIV-1 - Clinical Trials, accessed September 9, 2025, https://clinicaltrials.med.nyu.edu/clinicaltrial/2540/an-operationally-seamless-phase/
38. NCT06613685 | Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated | ClinicalTrials.gov, accessed September 9, 2025, https://clinicaltrials.gov/study/NCT06613685
39. Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated (WONDERS2) - Gilead Clinical Trials, accessed September 9, 2025, https://www.gileadclinicaltrials.com/study?nctid=NCT06613685
40. Gilead provides update on clinical studies evaluating GS-1720 and/or GS-4182 for the treatment of HIV-1 infection, accessed September 9, 2025, https://www.eatg.org/hiv-news/gilead-provides-update-on-clinical-studies-evaluating-gs-1720-and-or-gs-4182-for-the-treatment-of-hiv-1-infection/
41. GS-1720 - Drug Targets, Indications, Patents - Patsnap Synapse, accessed September 9, 2025, https://synapse.patsnap.com/drug/8ce012a45b2a482ead5d5d404fbe3fa7
42. Gilead Provides Update on Clinical Studies Evaluating GS-1720 and/or GS-4182 for the Treatment of HIV-1 Infection, accessed September 9, 2025, https://www.gilead.com/company/company-statements/2025/gilead-provides-update-on-clinical-studies-evaluating-gs-1720-and-or-gs-4182-for-the-treatment-of-hiv-1-infection
43. Merck Announces Clinical Holds on Studies Evaluating Islatravir for the Treatment and Prevention of HIV-1 Infection, accessed September 9, 2025, https://www.merck.com/news/merck-announces-clinical-holds-on-studies-evaluating-islatravir-for-the-treatment-and-prevention-of-hiv-1-infection/
44. FDA Places Clinical Hold on Gilead's HIV Combination Therapy Trials, accessed September 9, 2025, https://www.noahai.co/discover/article/7078
45. FDA slaps clinical hold on multiple Gilead HIV trials - Fierce Biotech, accessed September 9, 2025, https://www.fiercebiotech.com/biotech/fda-slaps-clinical-hold-multiple-gilead-hiv-combo-therapy-trials-shares-fall
46. Phase 2/3 studies put on hold for two once-weekly Gilead ..., accessed September 9, 2025, https://i-base.info/htb/51438
47. Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects - PMC - PubMed Central, accessed September 9, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8625745/
48. Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression | NIH, accessed September 9, 2025, https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/poor-cd4-cell-recovery-and-persistent
49. Gilead Sciences shares hit after HIV studies placed on hold by FDA - Investing.com, accessed September 9, 2025, https://www.investing.com/news/stock-market-news/gilead-sciences-shares-hit-after-hiv-studies-placed-on-hold-by-fda-4088959
50. Gilead Sciences Announces Second Quarter 2025 Financial Results, accessed September 9, 2025, https://www.gilead.com/news/news-details/2025/gilead-sciences-announces-second-quarter-2025-financial-results
51. Gilead Sciences Announces Second Quarter ... - Gilead Sciences, Inc., accessed September 9, 2025, https://investors.gilead.com/news/news-details/2025/Gilead-Sciences-Announces-Second-Quarter-2025-Financial-Results/default.aspx
52. Islatravir Patient Drug Record | NIH - Clinical Info HIV.gov, accessed September 9, 2025, https://clinicalinfo.hiv.gov/en/drugs/islatravir/patient
53. CD4 and white blood cell declines caused by islatravir are dose-related and reversible, but rule out using it for prevention | aidsmap, accessed September 9, 2025, https://www.aidsmap.com/news/oct-2022/cd4-and-white-blood-cell-declines-caused-islatravir-are-dose-related-and-reversible
54. Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial Human Immunodeficiency Virus Type 1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial | Clinical Infectious Diseases | Oxford Academic, accessed September 9, 2025, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf077/8074956
55. Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48, accessed September 9, 2025, https://www.gilead.com/news/news-details/2024/gilead-and-merck-announce-phase-2-data-showing-a-treatment-switch-to-an-investigational-oral-once-weekly-combination-regimen-of-islatravir-and-lenacapavir-maintained-viral-suppression-in-adu
56. Gilead's HIV Combo on Hold, With No Impact on FDA's Pending Lenacapavir Decision, accessed September 9, 2025, https://www.biospace.com/drug-development/gileads-hiv-combo-on-hold-with-no-impact-on-fdas-pending-lenacapavir-decision
57. Gilead data lends insight into transforming HIV prevention landscape, accessed September 9, 2025, https://www.europeanpharmaceuticalreview.com/news/236359/gilead-data-lends-insight-into-transforming-hiv-prevention-landscape/
58. Gilead Addresses Health Equity In HIV Prevention Challenges By Designing Next-Gen Clinical Trials Aiming For New Options, accessed September 9, 2025, https://www.clinicalleader.com/doc/gilead-addresses-health-equity-in-hiv-prevention-challenges-by-designing-next-gen-clinical-trials-aiming-for-new-options-0001
59. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD | Morningstar, accessed September 9, 2025, https://www.morningstar.com/news/globe-newswire/9487826/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-gilead-sciences-inc-gild
60. Gilead Sciences Stock Surges Despite FDA Clinical Hold on HIV Trials Ranking 98th in Market Activity - AInvest, accessed September 9, 2025, https://www.ainvest.com/news/gilead-sciences-stock-surges-fda-clinical-hold-hiv-trials-ranking-98th-market-activity-2506/
61. Gilead Sciences (GILD) Faces FDA Hold on HIV Drug Trials - GuruFocus, accessed September 9, 2025, https://www.gurufocus.com/news/2918958/gilead-sciences-gild-faces-fda-hold-on-hiv-drug-trials
62. Long-Acting Therapies -- Safety and Other Issues to Consider - TheBodyPro, accessed September 9, 2025, https://www.thebodypro.com/article/long-acting-therapies--safety-and-other-issues-to-
63. Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025 Including an Investigational Long Acting Twice Yearly Therapy Option, accessed September 9, 2025, https://www.gilead.com/news/news-details/2025/gilead-presents-new-hiv-treatment-and-cure-research-data-at-croi-2025-including-an-investigational-long-acting-twice-yearly-therapy-option